Bausch + Lomb (BLCO) Competitors $11.27 +0.08 (+0.71%) Closing price 03:59 PM EasternExtended Trading$11.09 -0.18 (-1.60%) As of 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BLCO vs. SOLV, SNN, PEN, STVN, GKOS, NARI, IRTC, INSP, TMDX, and SLNOShould you be buying Bausch + Lomb stock or one of its competitors? The main competitors of Bausch + Lomb include Solventum (SOLV), Smith & Nephew (SNN), Penumbra (PEN), Stevanato Group (STVN), Glaukos (GKOS), Inari Medical (NARI), iRhythm Technologies (IRTC), Inspire Medical Systems (INSP), TransMedics Group (TMDX), and Soleno Therapeutics (SLNO). These companies are all part of the "medical equipment" industry. Bausch + Lomb vs. Solventum Smith & Nephew Penumbra Stevanato Group Glaukos Inari Medical iRhythm Technologies Inspire Medical Systems TransMedics Group Soleno Therapeutics Bausch + Lomb (NYSE:BLCO) and Solventum (NYSE:SOLV) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership, earnings and community ranking. Do analysts recommend BLCO or SOLV? Bausch + Lomb presently has a consensus target price of $15.50, suggesting a potential upside of 37.53%. Solventum has a consensus target price of $80.29, suggesting a potential upside of 10.59%. Given Bausch + Lomb's stronger consensus rating and higher probable upside, equities analysts clearly believe Bausch + Lomb is more favorable than Solventum.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bausch + Lomb 1 Sell rating(s) 7 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.25Solventum 1 Sell rating(s) 7 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.10 Does the media favor BLCO or SOLV? In the previous week, Solventum had 6 more articles in the media than Bausch + Lomb. MarketBeat recorded 17 mentions for Solventum and 11 mentions for Bausch + Lomb. Solventum's average media sentiment score of 1.37 beat Bausch + Lomb's score of 0.70 indicating that Solventum is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 6 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Solventum 11 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better earnings and valuation, BLCO or SOLV? Solventum has higher revenue and earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than Solventum, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBausch + Lomb$4.83B0.82-$317M-$1.03-10.94Solventum$8.31B1.51$373.71M$2.1633.61 Is BLCO or SOLV more profitable? Solventum has a net margin of 0.00% compared to Bausch + Lomb's net margin of -6.62%. Bausch + Lomb's return on equity of 3.35% beat Solventum's return on equity.Company Net Margins Return on Equity Return on Assets Bausch + Lomb-6.62% 3.35% 1.66% Solventum N/A N/A N/A Do institutionals & insiders have more ownership in BLCO or SOLV? 11.1% of Bausch + Lomb shares are owned by institutional investors. 0.8% of Bausch + Lomb shares are owned by company insiders. Comparatively, 0.1% of Solventum shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in BLCO or SOLV? Bausch + Lomb received 39 more outperform votes than Solventum when rated by MarketBeat users. Likewise, 41.00% of users gave Bausch + Lomb an outperform vote while only 7.41% of users gave Solventum an outperform vote. CompanyUnderperformOutperformBausch + LombOutperform Votes4141.00% Underperform Votes5959.00% SolventumOutperform Votes27.41%Underperform Votes2592.59% SummaryBausch + Lomb beats Solventum on 9 of the 17 factors compared between the two stocks. Get Bausch + Lomb News Delivered to You Automatically Sign up to receive the latest news and ratings for BLCO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLCO vs. The Competition Export to ExcelMetricBausch + LombOphthalmic goods IndustryMedical SectorNYSE ExchangeMarket Cap$3.98B$10.50B$5.33B$19.30BDividend YieldN/A0.96%5.21%3.84%P/E Ratio-12.3833.9426.7134.53Price / Sales0.823.10386.1334.83Price / Cash8.4114.5338.2517.51Price / Book0.612.586.774.69Net Income-$317M$224.27M$3.23B$1.02B7 Day Performance-4.25%3.14%1.80%-1.74%1 Month Performance-9.73%18.06%11.10%7.50%1 Year Performance-23.28%-17.97%17.11%4.15% Bausch + Lomb Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLCOBausch + Lomb4.1301 of 5 stars$11.27+0.7%$15.50+37.5%-22.8%$3.98B$4.83B-12.3812,500Gap UpSOLVSolventum2.0076 of 5 stars$75.81+2.3%$80.29+5.9%+19.0%$13.12B$8.31B35.1022,000Positive NewsAnalyst UpgradeSNNSmith & Nephew2.2116 of 5 stars$29.09+0.7%$28.00-3.7%+11.0%$12.74B$5.81B13.4720,100News CoveragePENPenumbra4.7118 of 5 stars$280.89+0.1%$302.40+7.7%+35.0%$10.88B$1.24B826.153,900Positive NewsSTVNStevanato Group1.3372 of 5 stars€24.64+2.6%N/A+24.6%$7.46B$1.12B52.434,650Positive NewsGKOSGlaukos4.6181 of 5 stars$95.78+0.3%$134.67+40.6%-12.5%$5.47B$404.52M-33.37780Positive NewsAnalyst RevisionNARIInari Medical0.5859 of 5 stars$79.97flat$69.22-13.4%N/A$4.68B$493.63M-59.24800IRTCiRhythm Technologies1.2487 of 5 stars$141.78+0.6%$128.55-9.3%+52.9%$4.53B$618.59M-38.951,790Positive NewsAnalyst ForecastINSPInspire Medical Systems4.67 of 5 stars$149.86-1.8%$211.91+41.4%-4.0%$4.42B$840.11M86.62760Positive NewsTMDXTransMedics Group1.2881 of 5 stars$122.10+0.4%$126.70+3.8%-12.4%$4.13B$488.23M129.89210Positive NewsGap DownSLNOSoleno Therapeutics4.8494 of 5 stars$75.58+0.8%$106.78+41.3%+65.6%$3.81BN/A-22.7730News CoveragePositive News Related Companies and Tools Related Companies Solventum Competitors Smith & Nephew Competitors Penumbra Competitors Stevanato Group Competitors Glaukos Competitors Inari Medical Competitors iRhythm Technologies Competitors Inspire Medical Systems Competitors TransMedics Group Competitors Soleno Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:BLCO) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredMan who predicted $100K Bitcoin sees a huge run coming for another coin …Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election...Weiss Ratings | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredThe Secret Map of America, Declassified…Locked inside a Maryland man’s private safe is a map. But not just any map, mind you… This map shows a “...Banyan Hill Publishing | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bausch + Lomb Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bausch + Lomb With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
